Global CRM197 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR092416012

Publication Date:

September 24, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

CRM197 is a non-toxic mutant of diphtheria toxin and it"s widely used as a carrier protein for conjugate vaccines.
The global CRM197 market size was valued at US$ 182 million in 2023 and is forecast to a readjusted size of USD 258 million by 2030 with a CAGR of 5.1% during review period.
Pfizer Inc is one of the most important global manufacturers of CRM197, holds a share of over 85%. North America is the largest market, occupied for over 75%. In terms of type, research grade is the largest segment, with a share of over 85%. And in terms of application, pneumococcal conjugate vaccine segment holds a share of about 90%.
This report is a detailed and comprehensive analysis for global CRM197 market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global CRM197 market size and forecasts, in consumption value ($ Million), 2019-2030
Global CRM197 market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global CRM197 market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global CRM197 market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for CRM197
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global CRM197 market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Ligand Pharmaceuticals, CanSino Biologic, Beijing Kexing Biology Product, Scarab Genomics, Xpress Biologics, Fina Biosolutions, Eubiologics, EirGenix Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
CRM197 market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
CRM197 market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Research Grade CRM197
cGMP Grade CRM197
麻豆原创 segment by Application
Pneumococcal Conjugate Vaccine
Meningococcal Polysaccharide Conjugate Vaccine
Others
麻豆原创 segment by players, this report covers
Pfizer Inc.
Ligand Pharmaceuticals
CanSino Biologic
Beijing Kexing Biology Product
Scarab Genomics
Xpress Biologics
Fina Biosolutions
Eubiologics
EirGenix Inc.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe CRM197 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of CRM197, with revenue, gross margin, and global market share of CRM197 from 2019 to 2024.
Chapter 3, the CRM197 competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and CRM197 market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of CRM197.
Chapter 13, to describe CRM197 research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of CRM197 by Type
1.3.1 Overview: Global CRM197 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global CRM197 Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Research Grade CRM197
1.3.4 cGMP Grade CRM197
1.4 Global CRM197 麻豆原创 by Application
1.4.1 Overview: Global CRM197 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Pneumococcal Conjugate Vaccine
1.4.3 Meningococcal Polysaccharide Conjugate Vaccine
1.4.4 Others
1.5 Global CRM197 麻豆原创 Size & Forecast
1.6 Global CRM197 麻豆原创 Size and Forecast by Region
1.6.1 Global CRM197 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global CRM197 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America CRM197 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe CRM197 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific CRM197 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America CRM197 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa CRM197 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Pfizer Inc.
2.1.1 Pfizer Inc. Details
2.1.2 Pfizer Inc. Major Business
2.1.3 Pfizer Inc. CRM197 Product and Solutions
2.1.4 Pfizer Inc. CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Pfizer Inc. Recent Developments and Future Plans
2.2 Ligand Pharmaceuticals
2.2.1 Ligand Pharmaceuticals Details
2.2.2 Ligand Pharmaceuticals Major Business
2.2.3 Ligand Pharmaceuticals CRM197 Product and Solutions
2.2.4 Ligand Pharmaceuticals CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Ligand Pharmaceuticals Recent Developments and Future Plans
2.3 CanSino Biologic
2.3.1 CanSino Biologic Details
2.3.2 CanSino Biologic Major Business
2.3.3 CanSino Biologic CRM197 Product and Solutions
2.3.4 CanSino Biologic CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 CanSino Biologic Recent Developments and Future Plans
2.4 Beijing Kexing Biology Product
2.4.1 Beijing Kexing Biology Product Details
2.4.2 Beijing Kexing Biology Product Major Business
2.4.3 Beijing Kexing Biology Product CRM197 Product and Solutions
2.4.4 Beijing Kexing Biology Product CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Beijing Kexing Biology Product Recent Developments and Future Plans
2.5 Scarab Genomics
2.5.1 Scarab Genomics Details
2.5.2 Scarab Genomics Major Business
2.5.3 Scarab Genomics CRM197 Product and Solutions
2.5.4 Scarab Genomics CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Scarab Genomics Recent Developments and Future Plans
2.6 Xpress Biologics
2.6.1 Xpress Biologics Details
2.6.2 Xpress Biologics Major Business
2.6.3 Xpress Biologics CRM197 Product and Solutions
2.6.4 Xpress Biologics CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Xpress Biologics Recent Developments and Future Plans
2.7 Fina Biosolutions
2.7.1 Fina Biosolutions Details
2.7.2 Fina Biosolutions Major Business
2.7.3 Fina Biosolutions CRM197 Product and Solutions
2.7.4 Fina Biosolutions CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Fina Biosolutions Recent Developments and Future Plans
2.8 Eubiologics
2.8.1 Eubiologics Details
2.8.2 Eubiologics Major Business
2.8.3 Eubiologics CRM197 Product and Solutions
2.8.4 Eubiologics CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Eubiologics Recent Developments and Future Plans
2.9 EirGenix Inc.
2.9.1 EirGenix Inc. Details
2.9.2 EirGenix Inc. Major Business
2.9.3 EirGenix Inc. CRM197 Product and Solutions
2.9.4 EirGenix Inc. CRM197 Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 EirGenix Inc. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global CRM197 Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of CRM197 by Company Revenue
3.2.2 Top 3 CRM197 Players 麻豆原创 Share in 2023
3.2.3 Top 6 CRM197 Players 麻豆原创 Share in 2023
3.3 CRM197 麻豆原创: Overall Company Footprint Analysis
3.3.1 CRM197 麻豆原创: Region Footprint
3.3.2 CRM197 麻豆原创: Company Product Type Footprint
3.3.3 CRM197 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global CRM197 Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global CRM197 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global CRM197 Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global CRM197 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America CRM197 Consumption Value by Type (2019-2030)
6.2 North America CRM197 麻豆原创 Size by Application (2019-2030)
6.3 North America CRM197 麻豆原创 Size by Country
6.3.1 North America CRM197 Consumption Value by Country (2019-2030)
6.3.2 United States CRM197 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada CRM197 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico CRM197 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe CRM197 Consumption Value by Type (2019-2030)
7.2 Europe CRM197 Consumption Value by Application (2019-2030)
7.3 Europe CRM197 麻豆原创 Size by Country
7.3.1 Europe CRM197 Consumption Value by Country (2019-2030)
7.3.2 Germany CRM197 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France CRM197 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom CRM197 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia CRM197 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy CRM197 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific CRM197 Consumption Value by Type (2019-2030)
8.2 Asia-Pacific CRM197 Consumption Value by Application (2019-2030)
8.3 Asia-Pacific CRM197 麻豆原创 Size by Region
8.3.1 Asia-Pacific CRM197 Consumption Value by Region (2019-2030)
8.3.2 China CRM197 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan CRM197 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea CRM197 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India CRM197 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia CRM197 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia CRM197 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America CRM197 Consumption Value by Type (2019-2030)
9.2 South America CRM197 Consumption Value by Application (2019-2030)
9.3 South America CRM197 麻豆原创 Size by Country
9.3.1 South America CRM197 Consumption Value by Country (2019-2030)
9.3.2 Brazil CRM197 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina CRM197 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa CRM197 Consumption Value by Type (2019-2030)
10.2 Middle East & Africa CRM197 Consumption Value by Application (2019-2030)
10.3 Middle East & Africa CRM197 麻豆原创 Size by Country
10.3.1 Middle East & Africa CRM197 Consumption Value by Country (2019-2030)
10.3.2 Turkey CRM197 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia CRM197 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE CRM197 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 CRM197 麻豆原创 Drivers
11.2 CRM197 麻豆原创 Restraints
11.3 CRM197 Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 CRM197 Industry Chain
12.2 CRM197 Upstream Analysis
12.3 CRM197 Midstream Analysis
12.4 CRM197 Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Pfizer Inc.
Ligand Pharmaceuticals
CanSino Biologic
Beijing Kexing Biology Product
Scarab Genomics
Xpress Biologics
Fina Biosolutions
Eubiologics
EirGenix Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.